Aimmune Therapeutics Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Aimmune Therapeutics Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 24 Jun 2021 | Lorem |
| Aimmune’s Palforzia for peanut allergy use faces logistical challenges following COVID-19-induced changes in allergy practices, experts say | 17 Aug 2020 | Manasi Vaidya |
| Intrommune plans USD 8-10m raise in 2019 for peanut allergy therapy Phase I trial, atop current USD 1-2m fundraise for IND filing, CEO says | 10 Oct 2018 | Manasi Vaidya |
| Aimmune anticipates FDA AdCom prior to likely August 2019 approval decision for AR101 peanut allergy therapy; in ongoing reimbursement discussions, execs say | 17 Aug 2018 | Manasi Vaidya |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer